

Fall 10-19-2015

Headache be gone: Clearance of extractables and leachables in single-use technologies through ultrafiltration/diafiltration

Kate Lee
Genentech, lee.kate@gene.com

Nicholas Magarian
Genentech

Kunal Nagpal
Genentech

Ekta Mahajan
Genentech

Kenneth Skidmore
Genentech

Follow this and additional works at: <http://dc.engconfintl.org/biopoly>

 Part of the [Materials Science and Engineering Commons](#)

Recommended Citation

Kate Lee, Nicholas Magarian, Kunal Nagpal, Ekta Mahajan, and Kenneth Skidmore, "Headache be gone: Clearance of extractables and leachables in single-use technologies through ultrafiltration/diafiltration" in "Single-Use Technologies: Bridging Polymer Science to Biotechnology Applications", Ekta Mahajan, Genentech, Inc., USA Gary Lye, University College London, UK Eds, ECI Symposium Series, (2015). <http://dc.engconfintl.org/biopoly/7>

This Conference Proceeding is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Single-Use Technologies: Bridging Polymer Science to Biotechnology Applications by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.

HEADACHE BE GONE: CLEARANCE OF EXTRACTABLES AND LEACHABLES IN SINGLE-USE TECHNOLOGIES THROUGH ULTRAFILTRATION/DIAFILTRATION

Kate Lee, Genentech, Inc.
lee.kate@gene.com
Nicholas Magarian, Genentech, Inc.
Kunal Nagpal, Genentech, Inc.
Ekta Mahajan, Genentech, Inc.
Kenneth Skidmore, Genentech, Inc.

Key Words: Ultrafiltration/Diafiltration, Extractables, Leachables, Clearance, Single-Use Technology.

Application of single-use technologies in biopharmaceutical manufacturing can be driven by several factors such as reduced capital costs, reduced risk of cross-contamination, increased process flexibility, and reduced cleaning validation. However, implementation of single-use technologies have been restricted due to a number of concerns, with the most commonly cited being the presence of extractables and leachables (E/L) from single-use technologies. In general, overly conservative estimates of E/L are used in the risk assessment due to lack of data on clearance, resulting in a time-consuming, costly, and extensive E/L assessment for single-use technologies.

A proof-of-concept study is presented here to simplify these E/L assessments for qualification and implementation of single-use technologies in biopharmaceutical manufacturing. Results from the study indicated clearance of defined E/L in protein solutions. However, unexpected clearance phenomena were observed for specific groups of E/L, which will be discussed in detail.